Educational Event about LISRAYA (brepocitinib)
The US Food and Drug Administration (FDA) has approved Lisraya™ (brepocitinib) for the treatment of adults with dermatomyositis (DM). This approval marks the the first oral therapy specifically indicated for dermatomyositis and the first targeted therapy approved for this rare autoimmune disease. Learn more on TMA blog and join our upcoming webinar, where you will hear...